{
    "organizations": [],
    "uuid": "688f9de6f7273e756c996a03b85cc625f67e38e3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-reports-positi/brief-mabvax-therapeutics-reports-positive-safety-results-from-initial-cohort-of-mvt-1075-idUSASB0C7ZC",
    "ord_in_thread": 0,
    "title": "BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 40 PM / in 9 minutes BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075 Reuters Staff 1 Min Read Feb 28 (Reuters) - Mabvax Therapeutics Holdings Inc : * MABVAX THERAPEUTICS REPORTS POSITIVE SAFETY RESULTS FROM INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS * MABVAX THERAPEUTICS HOLDINGS INC - ACHIEVED PRIMARY OBJECTIVES IN EARLY-STAGE CLINICAL TRIAL OF NOVEL RADIOIMMUNOTHERAPY PRODUCT MVT-1075 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-02-28T14:39:00.000+02:00",
    "crawled": "2018-02-28T15:04:25.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "therapeutic",
        "report",
        "positive",
        "safety",
        "result",
        "initial",
        "cohort",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "mabvax",
        "therapeutic",
        "holding",
        "inc",
        "mabvax",
        "therapeutic",
        "report",
        "positive",
        "safety",
        "result",
        "initial",
        "cohort",
        "radioimmunotherapy",
        "phase",
        "trial",
        "treatment",
        "pancreatic",
        "colon",
        "lung",
        "cancer",
        "mabvax",
        "therapeutic",
        "holding",
        "inc",
        "achieved",
        "primary",
        "objective",
        "clinical",
        "trial",
        "novel",
        "radioimmunotherapy",
        "product",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}